LabTurbo Biotech Corporation
LabTurbo Biotech Corporation engages in the research, manufacture, and sale of gene detection systems and kits in Taiwan, the United States, the Czech Republic, Spain, France, Israel, Singapore, the Philippines, and Malaysia. It serves hospitals. The company was founded in 2000 and is based in Taipei, Taiwan.
LabTurbo Biotech Corporation (7725) - Total Assets
Latest total assets as of June 2025: NT$1.30 Billion TWD
Based on the latest financial reports, LabTurbo Biotech Corporation (7725) holds total assets worth NT$1.30 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
LabTurbo Biotech Corporation - Total Assets Trend (2021–2024)
This chart illustrates how LabTurbo Biotech Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
LabTurbo Biotech Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
LabTurbo Biotech Corporation's total assets of NT$1.30 Billion consist of 72.2% current assets and 27.8% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 12.6% |
| Accounts Receivable | NT$15.12 Million | 1.1% |
| Inventory | NT$98.50 Million | 7.1% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$16.45 Million | 1.2% |
| Goodwill | NT$26.97 Million | 1.9% |
Asset Composition Trend (2021–2024)
This chart illustrates how LabTurbo Biotech Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LabTurbo Biotech Corporation's current assets represent 72.2% of total assets in 2024, a decrease from 78.0% in 2021.
- Cash Position: Cash and equivalents constituted 12.6% of total assets in 2024, down from 44.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 4.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 7.1% of total assets.
LabTurbo Biotech Corporation Competitors by Total Assets
Key competitors of LabTurbo Biotech Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
LabTurbo Biotech Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - LabTurbo Biotech Corporation generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, LabTurbo Biotech Corporation generates $ 0.93 in net profit.
LabTurbo Biotech Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.89 | 15.63 | 6.43 |
| Quick Ratio | 13.44 | 14.56 | 5.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$870.31 Million | NT$ 968.40 Million | NT$ 1.13 Billion |
LabTurbo Biotech Corporation - Advanced Valuation Insights
This section examines the relationship between LabTurbo Biotech Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.98 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -0.9% |
| Total Assets | NT$1.39 Billion |
| Market Capitalization | $6.39K USD |
Valuation Analysis
Below Book Valuation: The market values LabTurbo Biotech Corporation's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: LabTurbo Biotech Corporation's assets decreased by 0.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for LabTurbo Biotech Corporation (2021–2024)
The table below shows the annual total assets of LabTurbo Biotech Corporation from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.39 Billion | -0.87% |
| 2023-12-31 | NT$1.40 Billion | -21.09% |
| 2022-12-31 | NT$1.78 Billion | +30.14% |
| 2021-12-31 | NT$1.36 Billion | -- |